Ascentage Pharma Group International (HKG:6855)
32.70
+0.78 (2.44%)
Jun 18, 2026, 4:08 PM HKT
HKG:6855 Revenue
In the year 2025, Ascentage Pharma Group International had annual revenue of 574.12M CNY, down -41.46%. Ascentage Pharma Group International had revenue of 340.42M in the half year ending December 31, 2025, with 329.37% growth.
Revenue
574.12M CNY
Revenue Growth
-41.46%
P/S Ratio
18.39
Revenue / Employee
748.53K CNY
Employees
767
Market Cap
11.75B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 574.12M | -406.53M | -41.46% |
| Dec 31, 2024 | 980.65M | 758.67M | 341.77% |
| Dec 31, 2023 | 221.98M | 12.27M | 5.85% |
| Dec 31, 2022 | 209.71M | 181.80M | 651.38% |
| Dec 31, 2021 | 27.91M | 15.46M | 124.18% |
| Dec 31, 2020 | 12.45M | -2.06M | -14.21% |
| Dec 31, 2019 | 14.51M | 7.71M | 113.21% |
| Dec 31, 2018 | 6.81M | 479.00K | 7.57% |
| Dec 31, 2017 | 6.33M | -1.34M | -17.46% |
| Dec 31, 2016 | 7.67M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Zai Lab | 3.55B |
| Everest Medicines | 1.90B |
| HBM Holdings | 1.23B |
| Nanjing Leads Biolabs | 197.25M |
| Suzhou Ribo Life Science | 165.26M |
| GenFleet Therapeutics (Shanghai) | 144.96M |
| CARsgen Therapeutics Holdings | 139.84M |
| Ascletis Pharma | 2.26M |
Ascentage Pharma Group International News
- 3 days ago - Ascentage Pharma assumed with an Outperform at Oppenheimer - TheFly
- 3 days ago - Ascentage Pharma announces clinical updates from EHA2026 - TheFly
- 3 days ago - Ascentage Pharma Presents Multiple Clinical Updates at EHA2026 Congress - GlobeNewsWire
- 7 days ago - Ascentage Pharma initiated with a Buy at B. Riley - TheFly
- 17 days ago - Ascentage Pharma presents data on olverembatinib - TheFly
- 17 days ago - Ascentage Pharma presents data from Phase 1b study of olverembatinib - TheFly
- 17 days ago - Ascentage Pharma presents first dataset of alrizomadlin - TheFly
- 17 days ago - Ascentage Pharma Presents Data on Olverembatinib in CML-LBP and Ph+ BCP-ALL at ASCO 2026 - GlobeNewsWire